ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with up to 4% of non-small cell lung cancer cases having a HER2 gene mutation.
Sevabertinib is an oral drug targeting HER2 mutations that shrinks tumors in advanced lung cancer patients, with minimal side effects.Â
FDA granted priority review for sevabertinib, and results of this study will help inform the decision. Â
BERLIN...
ESMO 2025: Targeted therapy plus radiation or surgery improves outcomes in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) the most common formÂ
Study reveals how bacteria in tumors drive treatment resistance in cancer
Researchers uncovered a previously unknown way for microbes within tumors to contribute to treatment resistance in certain cancers...
WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
KRAS G12C mutations are among the most common drivers of non-small cell lung cancer (NSCLC), yet first-line targeted therapy options remain limited. Olomorasib, a selective KRAS G12C inhibitor, has shown promising results in combination with chemoimmunotherapy. In an integrated analysis from the Phase I LOXO-RAS-20001 and Phase III SUNRAY-01 trials, Marcelo V. Negrao, M.D., and colleagues examined the safety and preliminary efficacy...
WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC
Pumitamig is a novel bispecific antibody targeting both the PD-L1 checkpoint and VEGF, a driver of angiogenesis, being studied in patients...
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC
Almost all patients with ALK-rearranged non-small cell lung cancer (NSCLC) end up with an incomplete response to targeted therapy with tyrosine...
WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer
Small cell lung cancer (SCLC)Â remains one of the most aggressive and difficult-to-treat forms of lung cancer, with few effective therapies...